UNITED STATES SECURITIES AND EXCHANGE COMMISSION Form 144 Filer Information Washington, D.C. 20549

FORM 144/A

NOTICE OF PROPOSED SALE OF SECURITIES

PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144/A: Filer Information

Filer CIK 0001638474 Filer CCC XXXXXXXX

Previous Accession Number Of The Filing 0001966249-24-000017

Form 144

Is this a LIVE or TEST Filing?

LIVE TEST

Submission Contact Information

Name

Phone

E-Mail Address

144/A: Issuer Information

Name of Issuer **Blueprint Medicines Corp**

SEC File Number 001-37359

45 Sidney Street Cambridge

Address of Issuer **MASSACHUSETTS**

02139

Phone 617-374-7580

Name of Person for Whose Account the Securities are To Be Sold Albers Jeffrey W.

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Director

144/A: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value		Approximate Date of Sale	Name the Securities Exchange
Common	Citigroup Global Markets Inc. 388 Greenwich Street New York NY 10013	5000	510000.00	6114723	11/07/2024	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144/A: Securities To Be Sold

Title of the	Date you	Nature of	Name of	Is	Date	Amount of	Date of	Nature of
Class	Acquired	Acquisition	Person from	this	Donor	Securities	Payment	Payment *

	11 ansaction	Acquired	Gift?	eu Acquireu	
COMMON	02/16/2017 Grant of vested options	Issuer		5000	02/16/2021 Compensation for services

^{*} If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144/A: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Albers, Jeffrey W. c/o Blueprint Medicines Corp. 45 Sydney Street Cambridge MA 02139	Common	09/09/2024	19702	1685911.00

144/A: Remarks and Signature

Remarks Amended to correct acquisition details concerning the shares sold hereunder.

Date of Notice 11/12/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

05/08/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ Aegis J. Frumento as a duly authorized representative of Citigroup Global

Markets Inc., as attorney-in-fact for JEFFREY W. ALBERS

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)